Opinion|Videos|February 19, 2025
Future of BCG in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?
Advertisement
Related to this article
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
2
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5